Securities · Claims Open

Biogen $25M Securities Settlement — Investors Who Bought BIIB From October 2019 to November 2020

Published November 17, 2026

Investors who bought or otherwise acquired Biogen Inc. (BIIB) common stock between October 22, 2019 and November 5, 2020 may qualify to claim a pro rata share of the $25 million Biogen securities class action settlement. Claims are open through January 19, 2027, and the settlement hearing is set for March 5, 2027.

Biogen securities class action settlement

Current Status

Claims are open. A claim must be submitted online by 11:59 p.m. ET on January 19, 2027, or mailed with a postmark no later than that date. Judge Indira Talwani of the U.S. District Court for the District of Massachusetts granted preliminary approval on October 27, 2026, and the settlement fairness hearing is set for March 5, 2027 at 10:00 a.m. ET. Nothing is paid unless the court grants final approval, and no payment date has been announced.

Status Claims Open
Claim Deadline January 19, 2027
Estimated Payout About $1.12 a share Before fees · July 22 – Nov. 5, 2020 buys · about $0.19 a share for earlier buys
Proof Required Yes Broker confirmations or account statements for every listed trade

What Changed Recently?

The claim period opened after the court preliminarily approved the settlement on October 27, 2026. Strategic Claims Services, the court-appointed claims administrator, is sending postcard and email notices and has posted the notice, claim form and settlement papers on its case page.

The case is Shash v. Biogen Inc., et al., No. 1:21-cv-10479-IT. It was first filed in November 2020 in federal court in California and moved to Massachusetts in 2021. Investors allege that Biogen and two former executives, former CEO Michel Vounatsos and former research head Alfred W. Sandrock, Jr., violated the federal securities laws by making false and misleading statements to investors. The settlement papers tie the case to Biogen's Alzheimer's drug aducanumab, which was then before the FDA, and to the stock's moves around a November 2020 FDA advisory committee meeting. Defendants deny all of the allegations and any wrongdoing, and the settlement is not an admission of liability.

The court dismissed the complaint in September 2022. In October 2023 the U.S. Court of Appeals for the First Circuit affirmed the dismissal except for claims based on one statement, which kept alive only claims for stock bought from July 22, 2020 on. The parties accepted a mediator's proposal on August 3, 2026 and signed the Stipulation of Settlement on October 6, 2026.

Who Qualifies?

The settlement class is all persons and entities that purchased or otherwise acquired Biogen common stock (Nasdaq: BIIB, CUSIP 09062X103) between October 22, 2019 and November 5, 2020, inclusive. Only publicly traded common stock counts. Shares received by gift or inheritance are not treated as purchases, and options and covering purchases on short sales are not eligible.

The defendants, their immediate families, Biogen's officers and directors during the class period and their families, and entities they control are excluded, along with anyone who opts out.

How Much Can You Get?

The $25 million fund is split into two pools, each divided pro rata among the claimants who qualify for it: Those figures are averages from the notice, not a prediction for any one investor. Each claim is scored by a recognized loss per share. Shares sold on or before November 5, 2020 get nothing. For shares held through February 2, 2021, the recognized loss is the lesser of $25.21 a share or the purchase price minus $255.32, the stock's 90-day average closing price after the disclosure. For shares sold between November 6, 2020 and February 2, 2021, the loss is the lesser of $25.21 or the purchase price minus the average closing price through the sale date. Purchases and sales are matched first-in, first-out.

A claimant with an overall trading gain, or who broke even, in Biogen stock during the class period receives nothing, and no payment under $10 is issued. Lead Counsel, The Rosen Law Firm, will ask for attorneys' fees of up to one-third of the fund ($8,333,333.33) plus up to $1.9 million in litigation expenses and up to $45,000 for the plaintiffs' own costs. All of it comes out of the fund, along with administration costs. Money left after redistribution goes to the Massachusetts Legal Assistance Corporation.

What Proof or Notice ID Is Required?

Brokerage records are required. The online claim form has an upload step, and the claim form asks for broker confirmation slips or account statements documenting every purchase and sale listed, plus holdings at the close of trading on October 21, 2019 and February 2, 2021. The transaction schedule must balance: beginning holdings plus purchases, minus sales and ending holdings, must equal zero. Claims filed without supporting documents can be rejected.

No notice ID or PIN is needed to file. Brokers, nominees and institutions filing for many accounts must use the administrator's electronic filing template instead of the online form.

What Is the Deadline?

Online claims are due by 11:59 p.m. ET on January 19, 2027; mailed claims must be postmarked by January 19, 2027. Other dates set by the court's order and the notice: The administrator's case page lists January 19, 2027 for objections; the court-approved notice and the preliminary approval order set the objection deadline at 21 days before the hearing, which is February 12, 2027.

How Do You Take Action?

Claims are filed through the online claim form on the Strategic Claims Services case page. The form runs in six steps: instructions, claimant information, a schedule of Biogen transactions, document upload and a signed certification. A confirmation email with a Form ID follows submission. A paper claim form is attached to the long-form notice for those who prefer to mail it.

What Happens Next?

Lead Counsel must file its papers supporting the settlement, the plan of allocation and the fee request at least 35 days before the March 5, 2027 hearing. At the hearing, the court will decide whether to grant final approval, approve the plan of allocation and rule on fees. The hearing can be moved or held remotely; any change is posted on the administrator's case page.

If the settlement is approved and becomes final, the administrator processes all claims and the court must approve the distribution before checks go out. No distribution date has been announced.

Sources and Verification



Questions

Why do purchases before July 22, 2020 get less?

In 2022 the court dismissed the complaint, and in 2023 the First Circuit revived only the claims based on a single statement. That left only purchases from July 22, 2020 through November 5, 2020 actively in the case. The plan of allocation reflects that difference: $20 million is set aside for those purchases and $5 million for the earlier, dismissed period, with each pool divided pro rata among the claimants in it.

Does someone who sold before November 6, 2020 get anything?

No. Under the plan of allocation, shares bought in the class period and sold on or before November 5, 2020 have a recognized loss of zero. Only shares still held after that date, or sold between November 6, 2020 and February 2, 2021, can produce a recognized loss.

Is this the same as the $18.9 million Biogen settlement?

No. That is a separate securities case covering Biogen stock bought in June and July 2021, after the FDA approved aducanumab. This $25 million settlement covers purchases from October 22, 2019 through November 5, 2020. Each has its own claim form and deadline.

Are small claims paid?

Not if the calculated payment is under $10. The plan of allocation says no distribution will be made on a claim whose payment would be less than $10.00. A claimant who had an overall trading gain or broke even in Biogen stock during the class period also receives nothing.

For more class actions keep scrolling below.
Settlement Amount $25,000,000 $20M for July 22 – Nov. 5, 2020 buys · $5M for Oct. 22, 2019 – July 21, 2020 buys
Case Title Shash v. Biogen Inc., et al.
Case Number 1:21-cv-10479-IT
Court U.S. District Court, District of Massachusetts
Final Approval Hearing March 5, 2027 at 10:00 AM ET Courtroom 9, Boston · Judge Indira Talwani · may be held remotely
Administrator Strategic Claims Services

More Open Securities Settlements